Roivant Social Ventures Donates to No Patient Left Behind
The 501(c)3 charity transfers its mission and legacy as it closes operations after six years.
Updated on Oct. 29, 2026 in Philanthropy
Live Poll
Do you believe current advocacy efforts successfully balance medical innovation with affordable drug prices?
Roivant Social Ventures has announced a six-figure donation to No Patient Left Behind to support efforts in improving drug affordability. The gift marks the conclusion of the public charity’s six-year operational history in New York City.
Why it matters
By funding No Patient Left Behind, the organization seeks to ensure its core mission regarding equitable drug access and research continues despite the closure of its own institution.
The donation follows a six-year period of operation for Roivant Social Ventures as a registered 501(c)3 public charity. The organization previously co-founded the Global Gene Therapy Initiative and the Catalyzing Access to Research and Equity in Representation Group.
The players
Roivant Social Ventures
A 501(c)3 public charity that previously co-founded the Global Gene Therapy Initiative and the Catalyzing Access to Research and Equity in Representation Group.
No Patient Left Behind
A professional network of healthcare stakeholders dedicated to improving drug affordability and access to medical research.
The details
No Patient Left Behind, a network of healthcare professionals and stakeholders, will incorporate the legacy and mission of the closing organization. The transfer is designed to sustain advocacy for patient access to medical research and equitable representation in the pharmaceutical sector.
Timeline
October 29, 2026: Roivant Social Ventures announces its final donation to No Patient Left Behind.
2020-2026: Duration of Roivant Social Ventures' operational existence.
Market Landscape
This transition follows established organizational patterns for non-profit entities seeking to ensure long-term mission fulfillment through institutional consolidation. By partnering with an existing network, the organization secures its legacy within the broader landscape of healthcare advocacy.
The donation does not change immediate retail prices for drugs or existing consumer healthcare services. Residents in New York City and beyond will see the organization’s previous mission goals continued through the work of the receiving network.
The takeaway
The move demonstrates a strategic approach to non-profit closure by ensuring funds remain dedicated to established advocacy goals. Donors and stakeholders can continue to track progress through the ongoing activities of the recipient network.
Further reading
Learn more about local efforts in Philanthropy.
More information
Review the organization's mission and future research initiatives on the No Patient Left Behind official website.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you believe current advocacy efforts successfully balance medical innovation with affordable drug prices?
